YUBO INTERNATIONAL BIOTECH LIMITED
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $12.4K | $0 | $0 | $0 | $-18 | $0 |
| Cost of Revenue | $0 | $0 | $4.2K | $0 | $0 | $0 | $-5 | $0 |
| Gross Profit | $0 | $0 | $8.2K | $0 | $0 | $0 | $-13 | $0 |
| Gross Margin | — | — | 66.1% | — | — | — | 72.2% | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | — | — | — | — | — | — | — | — |
| Operating Income | $-238.9K | $-289.3K | $-160.6K | $-310.1K | $-249.7K | $-467.3K | $-357.3K | $-532.8K |
| Operating Margin | — | — | -1,299.8% | — | — | — | 1,984,988.9% | — |
| Interest Expense | — | — | — | $18 | $23 | — | — | $49 |
| Pretax Income | $-268.7K | $-295.0K | $-160.7K | $-310.2K | $-249.7K | $-467.3K | $-352.9K | $-621.1K |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-247.9K | $-272.6K | $-103.1K | $-310.2K | $-230.3K | $-435.6K | $-249.8K | $-621.1K |
| Net Margin | — | — | -834.9% | — | — | — | 1,387,716.7% | — |
| EPS (Basic) | — | — | — | — | — | — | — | — |
| EPS (Diluted) | $0.00 | $0.00 | $-0.01 | $0.00 | $0.00 | $0.00 | $-0.01 | $0.00 |
| Shares Outstanding (Basic) | — | — | — | — | — | — | — | — |
| Shares Outstanding (Diluted) | 170.4M | 170.4M | 139.6M | 147.9M | 119.8M | 119.8M | 119.8M | 1.20B |
| Dividends Per Share | — | — | — | — | — | — | — | — |